nodes	percent_of_prediction	percent_of_DWPC	metapath
Paricalcitol—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0619	0.463	CbGbCtD
Paricalcitol—CYP3A4—Progesterone—uterine cancer	0.041	0.306	CbGbCtD
Paricalcitol—CYP3A4—Etoposide—uterine cancer	0.0184	0.137	CbGbCtD
Paricalcitol—CYP24A1—Metabolism of steroid hormones and vitamin D—SRD5A2—uterine cancer	0.0154	0.0711	CbGpPWpGaD
Paricalcitol—CYP3A4—Doxorubicin—uterine cancer	0.0125	0.0935	CbGbCtD
Paricalcitol—CYP24A1—Metabolism of steroid hormones and vitamin D—AKR1B1—uterine cancer	0.0111	0.0514	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of steroid hormones and vitamin D—STAR—uterine cancer	0.0111	0.0514	CbGpPWpGaD
Paricalcitol—CYP24A1—renal system—uterine cancer	0.00988	0.104	CbGeAlD
Paricalcitol—UGT1A4—renal system—uterine cancer	0.00988	0.104	CbGeAlD
Paricalcitol—CYP24A1—endometrium—uterine cancer	0.00955	0.1	CbGeAlD
Paricalcitol—CYP24A1—female reproductive system—uterine cancer	0.00791	0.0832	CbGeAlD
Paricalcitol—CYP24A1—vagina—uterine cancer	0.00716	0.0753	CbGeAlD
Paricalcitol—CYP24A1—Metabolism of steroid hormones and vitamin D—CYP11A1—uterine cancer	0.00666	0.0308	CbGpPWpGaD
Paricalcitol—VDR—epithelium—uterine cancer	0.00586	0.0617	CbGeAlD
Paricalcitol—VDR—uterine cervix—uterine cancer	0.00581	0.0612	CbGeAlD
Paricalcitol—VDR—Ovarian Infertility Genes—MLH1—uterine cancer	0.00555	0.0257	CbGpPWpGaD
Paricalcitol—VDR—decidua—uterine cancer	0.00554	0.0583	CbGeAlD
Paricalcitol—Cholecalciferol—CYP11A1—uterine cancer	0.00553	1	CrCbGaD
Paricalcitol—VDR—renal system—uterine cancer	0.00544	0.0572	CbGeAlD
Paricalcitol—VDR—Ovarian Infertility Genes—PGR—uterine cancer	0.00526	0.0243	CbGpPWpGaD
Paricalcitol—VDR—mammalian vulva—uterine cancer	0.00509	0.0535	CbGeAlD
Paricalcitol—CYP24A1—Metabolism of steroid hormones and vitamin D—CYP19A1—uterine cancer	0.0049	0.0226	CbGpPWpGaD
Paricalcitol—VDR—uterus—uterine cancer	0.00485	0.051	CbGeAlD
Paricalcitol—VDR—Ovarian Infertility Genes—ESR2—uterine cancer	0.00464	0.0214	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—NFE2L2—uterine cancer	0.00461	0.0213	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors—PGR—uterine cancer	0.00459	0.0212	CbGpPWpGaD
Paricalcitol—VDR—female reproductive system—uterine cancer	0.00436	0.0458	CbGeAlD
Paricalcitol—VDR—Ovarian Infertility Genes—CYP19A1—uterine cancer	0.00421	0.0194	CbGpPWpGaD
Paricalcitol—CYP24A1—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.00413	0.0191	CbGpPWpGaD
Paricalcitol—CYP24A1—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.00407	0.0188	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors—ESR2—uterine cancer	0.00404	0.0187	CbGpPWpGaD
Paricalcitol—VDR—female gonad—uterine cancer	0.00396	0.0417	CbGeAlD
Paricalcitol—VDR—vagina—uterine cancer	0.00394	0.0414	CbGeAlD
Paricalcitol—VDR—Nuclear Receptor transcription pathway—PGR—uterine cancer	0.00363	0.0167	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of deltaNp63 isoforms—FBXW7—uterine cancer	0.00354	0.0164	CbGpPWpGaD
Paricalcitol—VDR—Ovarian Infertility Genes—SMAD3—uterine cancer	0.00344	0.0159	CbGpPWpGaD
Paricalcitol—CYP24A1—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.00335	0.0155	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptor transcription pathway—ESR2—uterine cancer	0.00319	0.0147	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—AKR1B10—uterine cancer	0.00315	0.0146	CbGpPWpGaD
Paricalcitol—CYP24A1—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.00304	0.014	CbGpPWpGaD
Paricalcitol—CYP3A4—Benzo(a)pyrene metabolism—AKR1C1—uterine cancer	0.003	0.0138	CbGpPWpGaD
Paricalcitol—CYP24A1—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.003	0.0138	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—AKR1B1—uterine cancer	0.00293	0.0135	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—PMS2—uterine cancer	0.00281	0.013	CbGpPWpGaD
Paricalcitol—VDR—lymph node—uterine cancer	0.00255	0.0268	CbGeAlD
Paricalcitol—UGT1A4—Metapathway biotransformation—AKR1B10—uterine cancer	0.00252	0.0116	CbGpPWpGaD
Paricalcitol—CYP24A1—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.00246	0.0114	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors—ESR1—uterine cancer	0.00245	0.0113	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—AKR1B1—uterine cancer	0.00234	0.0108	CbGpPWpGaD
Paricalcitol—CYP3A4—Benzo(a)pyrene metabolism—AKR1C3—uterine cancer	0.00231	0.0107	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—AKR1C1—uterine cancer	0.00215	0.00993	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptor transcription pathway—ESR1—uterine cancer	0.00194	0.00894	CbGpPWpGaD
Paricalcitol—VDR—Ovarian Infertility Genes—CDKN1B—uterine cancer	0.00191	0.00883	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—MSH2—uterine cancer	0.00189	0.00874	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—GPX3—uterine cancer	0.00189	0.00872	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—NFE2L2—uterine cancer	0.00183	0.00845	CbGpPWpGaD
Paricalcitol—CYP3A4—renal system—uterine cancer	0.00182	0.0191	CbGeAlD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—CDKN2B—uterine cancer	0.00179	0.00829	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—CYP11A1—uterine cancer	0.00178	0.00821	CbGpPWpGaD
Paricalcitol—VDR—Retinoic acid receptors-mediated signaling—EP300—uterine cancer	0.00177	0.00816	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—CYP11A1—uterine cancer	0.00175	0.0081	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—GPX3—uterine cancer	0.00175	0.00806	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—AKR1C1—uterine cancer	0.00172	0.00794	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—MLH1—uterine cancer	0.00171	0.00788	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—AKR1C3—uterine cancer	0.00166	0.00765	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—SMAD3—uterine cancer	0.00164	0.00757	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—uterine cancer	0.00159	0.00733	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.00158	0.00729	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—GPX3—uterine cancer	0.00151	0.00697	CbGpPWpGaD
Paricalcitol—CYP3A4—female reproductive system—uterine cancer	0.00146	0.0153	CbGeAlD
Paricalcitol—UGT1A4—Biological oxidations—CYP11A1—uterine cancer	0.00142	0.00656	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—CDKN2A—uterine cancer	0.00142	0.00656	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—CYP11A1—uterine cancer	0.0014	0.00647	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	0.00136	0.0063	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—ESR1—uterine cancer	0.00134	0.00618	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—AKR1C3—uterine cancer	0.00132	0.00611	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—CYP19A1—uterine cancer	0.00131	0.00604	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—CYP19A1—uterine cancer	0.00129	0.00596	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	0.0012	0.00553	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.00114	0.00527	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.00114	0.00527	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—EP300—uterine cancer	0.0011	0.0051	CbGpPWpGaD
Paricalcitol—VDR—Retinoic acid receptors-mediated signaling—AKT1—uterine cancer	0.00107	0.00493	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—CYP19A1—uterine cancer	0.00105	0.00483	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—CYP19A1—uterine cancer	0.00103	0.00476	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—MET—uterine cancer	0.000867	0.004	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—PHF1—uterine cancer	0.00085	0.00393	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000838	0.00387	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—EP300—uterine cancer	0.000798	0.00369	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—CHD4—uterine cancer	0.000723	0.00334	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—SRD5A2—uterine cancer	0.000703	0.00325	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—NDUFB11—uterine cancer	0.000703	0.00325	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000683	0.00315	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.000645	0.00298	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—PGR—uterine cancer	0.000626	0.00289	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—SUZ12—uterine cancer	0.000606	0.0028	CbGpPWpGaD
Paricalcitol—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	0.000565	0.00103	CcSEcCtD
Paricalcitol—Osteoarthritis—Epirubicin—uterine cancer	0.000565	0.00103	CcSEcCtD
Paricalcitol—Feeling abnormal—Dactinomycin—uterine cancer	0.000564	0.00103	CcSEcCtD
Paricalcitol—Ill-defined disorder—Etoposide—uterine cancer	0.000563	0.00103	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—NDUFB11—uterine cancer	0.000562	0.0026	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—SRD5A2—uterine cancer	0.000562	0.0026	CbGpPWpGaD
Paricalcitol—Anaemia—Etoposide—uterine cancer	0.000561	0.00102	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Dactinomycin—uterine cancer	0.00056	0.00102	CcSEcCtD
Paricalcitol—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000558	0.00102	CcSEcCtD
Paricalcitol—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000553	0.00101	CcSEcCtD
Paricalcitol—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000553	0.00101	CcSEcCtD
Paricalcitol—VDR—Generic Transcription Pathway—ESR2—uterine cancer	0.000551	0.00255	CbGpPWpGaD
Paricalcitol—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00055	0.001	CcSEcCtD
Paricalcitol—Malaise—Etoposide—uterine cancer	0.000547	0.000997	CcSEcCtD
Paricalcitol—Dermatitis bullous—Doxorubicin—uterine cancer	0.000547	0.000996	CcSEcCtD
Paricalcitol—Vertigo—Etoposide—uterine cancer	0.000545	0.000993	CcSEcCtD
Paricalcitol—Leukopenia—Etoposide—uterine cancer	0.000543	0.00099	CcSEcCtD
Paricalcitol—Abdominal pain—Dactinomycin—uterine cancer	0.000541	0.000986	CcSEcCtD
Paricalcitol—Body temperature increased—Dactinomycin—uterine cancer	0.000541	0.000986	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—PTEN—uterine cancer	0.00054	0.0025	CbGpPWpGaD
Paricalcitol—Cardiac arrest—Epirubicin—uterine cancer	0.000537	0.000979	CcSEcCtD
Paricalcitol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000536	0.00247	CbGpPWpGaD
Paricalcitol—Hypoglycaemia—Doxorubicin—uterine cancer	0.000536	0.000976	CcSEcCtD
Paricalcitol—Loss of consciousness—Etoposide—uterine cancer	0.000534	0.000972	CcSEcCtD
Paricalcitol—Cerebrovascular accident—Doxorubicin—uterine cancer	0.000534	0.000972	CcSEcCtD
Paricalcitol—Cough—Etoposide—uterine cancer	0.00053	0.000965	CcSEcCtD
Paricalcitol—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000529	0.00244	CbGpPWpGaD
Paricalcitol—Dehydration—Epirubicin—uterine cancer	0.000526	0.000957	CcSEcCtD
Paricalcitol—Hypertension—Etoposide—uterine cancer	0.000524	0.000955	CcSEcCtD
Paricalcitol—Osteoarthritis—Doxorubicin—uterine cancer	0.000523	0.000952	CcSEcCtD
Paricalcitol—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.000523	0.000952	CcSEcCtD
Paricalcitol—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000521	0.00095	CcSEcCtD
Paricalcitol—Chest pain—Etoposide—uterine cancer	0.000517	0.000941	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—EP300—uterine cancer	0.000515	0.00238	CbGpPWpGaD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000513	0.000935	CcSEcCtD
Paricalcitol—Discomfort—Etoposide—uterine cancer	0.000511	0.00093	CcSEcCtD
Paricalcitol—Breast disorder—Epirubicin—uterine cancer	0.000511	0.00093	CcSEcCtD
Paricalcitol—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000509	0.000927	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—AKR1B1—uterine cancer	0.000508	0.00235	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—STAR—uterine cancer	0.000508	0.00235	CbGpPWpGaD
Paricalcitol—Nasopharyngitis—Epirubicin—uterine cancer	0.000505	0.00092	CcSEcCtD
Paricalcitol—Hypersensitivity—Dactinomycin—uterine cancer	0.000504	0.000919	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	0.000502	0.00232	CbGpPWpGaD
Paricalcitol—Gastritis—Epirubicin—uterine cancer	0.0005	0.000911	CcSEcCtD
Paricalcitol—Confusional state—Etoposide—uterine cancer	0.0005	0.00091	CcSEcCtD
Paricalcitol—Cardiac arrest—Doxorubicin—uterine cancer	0.000497	0.000906	CcSEcCtD
Paricalcitol—Infection—Etoposide—uterine cancer	0.000492	0.000897	CcSEcCtD
Paricalcitol—Asthenia—Dactinomycin—uterine cancer	0.000491	0.000895	CcSEcCtD
Paricalcitol—Influenza—Epirubicin—uterine cancer	0.000488	0.00089	CcSEcCtD
Paricalcitol—Dysphagia—Epirubicin—uterine cancer	0.000488	0.00089	CcSEcCtD
Paricalcitol—Asthma—Epirubicin—uterine cancer	0.000488	0.00089	CcSEcCtD
Paricalcitol—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	0.000488	0.00225	CbGpPWpGaD
Paricalcitol—Dehydration—Doxorubicin—uterine cancer	0.000486	0.000886	CcSEcCtD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—AKT1—uterine cancer	0.000482	0.00223	CbGpPWpGaD
Paricalcitol—Skin disorder—Etoposide—uterine cancer	0.000481	0.000877	CcSEcCtD
Paricalcitol—Hyperhidrosis—Etoposide—uterine cancer	0.000479	0.000872	CcSEcCtD
Paricalcitol—Pancreatitis—Epirubicin—uterine cancer	0.000479	0.000872	CcSEcCtD
Paricalcitol—Breast disorder—Doxorubicin—uterine cancer	0.000473	0.000861	CcSEcCtD
Paricalcitol—Anorexia—Etoposide—uterine cancer	0.000472	0.00086	CcSEcCtD
Paricalcitol—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000471	0.000858	CcSEcCtD
Paricalcitol—Diarrhoea—Dactinomycin—uterine cancer	0.000468	0.000853	CcSEcCtD
Paricalcitol—Nasopharyngitis—Doxorubicin—uterine cancer	0.000468	0.000852	CcSEcCtD
Paricalcitol—Hypotension—Etoposide—uterine cancer	0.000463	0.000843	CcSEcCtD
Paricalcitol—Gastritis—Doxorubicin—uterine cancer	0.000463	0.000843	CcSEcCtD
Paricalcitol—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000454	0.000827	CcSEcCtD
Paricalcitol—Asthma—Doxorubicin—uterine cancer	0.000452	0.000823	CcSEcCtD
Paricalcitol—Influenza—Doxorubicin—uterine cancer	0.000452	0.000823	CcSEcCtD
Paricalcitol—Dysphagia—Doxorubicin—uterine cancer	0.000452	0.000823	CcSEcCtD
Paricalcitol—VDR—Generic Transcription Pathway—CDKN2B—uterine cancer	0.000449	0.00207	CbGpPWpGaD
Paricalcitol—Paraesthesia—Etoposide—uterine cancer	0.000445	0.00081	CcSEcCtD
Paricalcitol—Pancreatitis—Doxorubicin—uterine cancer	0.000443	0.000807	CcSEcCtD
Paricalcitol—Weight decreased—Epirubicin—uterine cancer	0.000442	0.000805	CcSEcCtD
Paricalcitol—Dyspnoea—Etoposide—uterine cancer	0.000442	0.000805	CcSEcCtD
Paricalcitol—Somnolence—Etoposide—uterine cancer	0.00044	0.000802	CcSEcCtD
Paricalcitol—Pneumonia—Epirubicin—uterine cancer	0.000438	0.000798	CcSEcCtD
Paricalcitol—Infestation NOS—Epirubicin—uterine cancer	0.000435	0.000793	CcSEcCtD
Paricalcitol—Infestation—Epirubicin—uterine cancer	0.000435	0.000793	CcSEcCtD
Paricalcitol—Vomiting—Dactinomycin—uterine cancer	0.000435	0.000793	CcSEcCtD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000434	0.00201	CbGpPWpGaD
Paricalcitol—Rash—Dactinomycin—uterine cancer	0.000432	0.000786	CcSEcCtD
Paricalcitol—Decreased appetite—Etoposide—uterine cancer	0.000431	0.000785	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Etoposide—uterine cancer	0.000428	0.000779	CcSEcCtD
Paricalcitol—Fatigue—Etoposide—uterine cancer	0.000427	0.000778	CcSEcCtD
Paricalcitol—Pain—Etoposide—uterine cancer	0.000424	0.000772	CcSEcCtD
Paricalcitol—Constipation—Etoposide—uterine cancer	0.000424	0.000772	CcSEcCtD
Paricalcitol—Conjunctivitis—Epirubicin—uterine cancer	0.000423	0.000771	CcSEcCtD
Paricalcitol—Urinary tract infection—Epirubicin—uterine cancer	0.000423	0.000771	CcSEcCtD
Paricalcitol—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.00042	0.000765	CcSEcCtD
Paricalcitol—Sweating—Epirubicin—uterine cancer	0.000417	0.00076	CcSEcCtD
Paricalcitol—Epistaxis—Epirubicin—uterine cancer	0.000411	0.000748	CcSEcCtD
Paricalcitol—VDR—Generic Transcription Pathway—SMAD3—uterine cancer	0.00041	0.00189	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	0.000409	0.00189	CbGpPWpGaD
Paricalcitol—Weight decreased—Doxorubicin—uterine cancer	0.000409	0.000745	CcSEcCtD
Paricalcitol—Sinusitis—Epirubicin—uterine cancer	0.000409	0.000744	CcSEcCtD
Paricalcitol—Feeling abnormal—Etoposide—uterine cancer	0.000408	0.000744	CcSEcCtD
Paricalcitol—Nausea—Dactinomycin—uterine cancer	0.000407	0.000741	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—STAR—uterine cancer	0.000406	0.00188	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—AKR1B1—uterine cancer	0.000406	0.00188	CbGpPWpGaD
Paricalcitol—Pneumonia—Doxorubicin—uterine cancer	0.000405	0.000738	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Etoposide—uterine cancer	0.000405	0.000738	CcSEcCtD
Paricalcitol—Infestation—Doxorubicin—uterine cancer	0.000403	0.000734	CcSEcCtD
Paricalcitol—Infestation NOS—Doxorubicin—uterine cancer	0.000403	0.000734	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—POLD1—uterine cancer	0.000399	0.00184	CbGpPWpGaD
Paricalcitol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000394	0.00182	CbGpPWpGaD
Paricalcitol—Urticaria—Etoposide—uterine cancer	0.000394	0.000717	CcSEcCtD
Paricalcitol—Body temperature increased—Etoposide—uterine cancer	0.000392	0.000713	CcSEcCtD
Paricalcitol—Abdominal pain—Etoposide—uterine cancer	0.000392	0.000713	CcSEcCtD
Paricalcitol—Urinary tract infection—Doxorubicin—uterine cancer	0.000392	0.000713	CcSEcCtD
Paricalcitol—Conjunctivitis—Doxorubicin—uterine cancer	0.000392	0.000713	CcSEcCtD
Paricalcitol—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000389	0.0018	CbGpPWpGaD
Paricalcitol—Hypoaesthesia—Epirubicin—uterine cancer	0.000389	0.000708	CcSEcCtD
Paricalcitol—Pharyngitis—Epirubicin—uterine cancer	0.000388	0.000707	CcSEcCtD
Paricalcitol—Sweating—Doxorubicin—uterine cancer	0.000386	0.000704	CcSEcCtD
Paricalcitol—Urinary tract disorder—Epirubicin—uterine cancer	0.000386	0.000703	CcSEcCtD
Paricalcitol—Oedema peripheral—Epirubicin—uterine cancer	0.000385	0.000701	CcSEcCtD
Paricalcitol—Connective tissue disorder—Epirubicin—uterine cancer	0.000384	0.0007	CcSEcCtD
Paricalcitol—Urethral disorder—Epirubicin—uterine cancer	0.000383	0.000698	CcSEcCtD
Paricalcitol—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	0.00038	0.00176	CbGpPWpGaD
Paricalcitol—Epistaxis—Doxorubicin—uterine cancer	0.00038	0.000692	CcSEcCtD
Paricalcitol—Sinusitis—Doxorubicin—uterine cancer	0.000378	0.000689	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—AKR1C1—uterine cancer	0.000373	0.00172	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—TP53—uterine cancer	0.000369	0.0017	CbGpPWpGaD
Paricalcitol—Eye disorder—Epirubicin—uterine cancer	0.000365	0.000665	CcSEcCtD
Paricalcitol—Hypersensitivity—Etoposide—uterine cancer	0.000365	0.000665	CcSEcCtD
Paricalcitol—Cardiac disorder—Epirubicin—uterine cancer	0.000363	0.000661	CcSEcCtD
Paricalcitol—Hypoaesthesia—Doxorubicin—uterine cancer	0.00036	0.000656	CcSEcCtD
Paricalcitol—Pharyngitis—Doxorubicin—uterine cancer	0.000359	0.000654	CcSEcCtD
Paricalcitol—Urinary tract disorder—Doxorubicin—uterine cancer	0.000357	0.000651	CcSEcCtD
Paricalcitol—Oedema peripheral—Doxorubicin—uterine cancer	0.000356	0.000649	CcSEcCtD
Paricalcitol—Asthenia—Etoposide—uterine cancer	0.000356	0.000647	CcSEcCtD
Paricalcitol—Connective tissue disorder—Doxorubicin—uterine cancer	0.000355	0.000647	CcSEcCtD
Paricalcitol—Angiopathy—Epirubicin—uterine cancer	0.000355	0.000646	CcSEcCtD
Paricalcitol—Urethral disorder—Doxorubicin—uterine cancer	0.000355	0.000646	CcSEcCtD
Paricalcitol—Immune system disorder—Epirubicin—uterine cancer	0.000353	0.000643	CcSEcCtD
Paricalcitol—Mediastinal disorder—Epirubicin—uterine cancer	0.000352	0.000642	CcSEcCtD
Paricalcitol—Chills—Epirubicin—uterine cancer	0.000351	0.000639	CcSEcCtD
Paricalcitol—Pruritus—Etoposide—uterine cancer	0.000351	0.000638	CcSEcCtD
Paricalcitol—Arrhythmia—Epirubicin—uterine cancer	0.000349	0.000636	CcSEcCtD
Paricalcitol—Alopecia—Epirubicin—uterine cancer	0.000345	0.000629	CcSEcCtD
Paricalcitol—Mental disorder—Epirubicin—uterine cancer	0.000343	0.000624	CcSEcCtD
Paricalcitol—Malnutrition—Epirubicin—uterine cancer	0.00034	0.00062	CcSEcCtD
Paricalcitol—Diarrhoea—Etoposide—uterine cancer	0.000339	0.000617	CcSEcCtD
Paricalcitol—Eye disorder—Doxorubicin—uterine cancer	0.000338	0.000616	CcSEcCtD
Paricalcitol—Cardiac disorder—Doxorubicin—uterine cancer	0.000336	0.000611	CcSEcCtD
Paricalcitol—VDR—Generic Transcription Pathway—ESR1—uterine cancer	0.000334	0.00154	CbGpPWpGaD
Paricalcitol—Tension—Epirubicin—uterine cancer	0.000334	0.000608	CcSEcCtD
Paricalcitol—Dysgeusia—Epirubicin—uterine cancer	0.000333	0.000607	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—RRM2—uterine cancer	0.000332	0.00154	CbGpPWpGaD
Paricalcitol—Nervousness—Epirubicin—uterine cancer	0.000331	0.000602	CcSEcCtD
Paricalcitol—Back pain—Epirubicin—uterine cancer	0.000329	0.0006	CcSEcCtD
Paricalcitol—Angiopathy—Doxorubicin—uterine cancer	0.000328	0.000598	CcSEcCtD
Paricalcitol—Dizziness—Etoposide—uterine cancer	0.000328	0.000597	CcSEcCtD
Paricalcitol—Muscle spasms—Epirubicin—uterine cancer	0.000327	0.000596	CcSEcCtD
Paricalcitol—Immune system disorder—Doxorubicin—uterine cancer	0.000327	0.000595	CcSEcCtD
Paricalcitol—Mediastinal disorder—Doxorubicin—uterine cancer	0.000326	0.000594	CcSEcCtD
Paricalcitol—Chills—Doxorubicin—uterine cancer	0.000325	0.000591	CcSEcCtD
Paricalcitol—Arrhythmia—Doxorubicin—uterine cancer	0.000323	0.000589	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—DCN—uterine cancer	0.000323	0.00149	CbGpPWpGaD
Paricalcitol—Alopecia—Doxorubicin—uterine cancer	0.00032	0.000582	CcSEcCtD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.00032	0.00148	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—POLD1—uterine cancer	0.000319	0.00147	CbGpPWpGaD
Paricalcitol—Mental disorder—Doxorubicin—uterine cancer	0.000317	0.000577	CcSEcCtD
Paricalcitol—Ill-defined disorder—Epirubicin—uterine cancer	0.000316	0.000575	CcSEcCtD
Paricalcitol—Vomiting—Etoposide—uterine cancer	0.000315	0.000574	CcSEcCtD
Paricalcitol—Malnutrition—Doxorubicin—uterine cancer	0.000315	0.000574	CcSEcCtD
Paricalcitol—Anaemia—Epirubicin—uterine cancer	0.000315	0.000573	CcSEcCtD
Paricalcitol—Agitation—Epirubicin—uterine cancer	0.000313	0.00057	CcSEcCtD
Paricalcitol—Rash—Etoposide—uterine cancer	0.000312	0.000569	CcSEcCtD
Paricalcitol—Dermatitis—Etoposide—uterine cancer	0.000312	0.000568	CcSEcCtD
Paricalcitol—Headache—Etoposide—uterine cancer	0.00031	0.000565	CcSEcCtD
Paricalcitol—Tension—Doxorubicin—uterine cancer	0.000309	0.000563	CcSEcCtD
Paricalcitol—Dysgeusia—Doxorubicin—uterine cancer	0.000308	0.000562	CcSEcCtD
Paricalcitol—Malaise—Epirubicin—uterine cancer	0.000307	0.000559	CcSEcCtD
Paricalcitol—Nervousness—Doxorubicin—uterine cancer	0.000306	0.000557	CcSEcCtD
Paricalcitol—Vertigo—Epirubicin—uterine cancer	0.000306	0.000557	CcSEcCtD
Paricalcitol—Syncope—Epirubicin—uterine cancer	0.000305	0.000556	CcSEcCtD
Paricalcitol—Leukopenia—Epirubicin—uterine cancer	0.000305	0.000555	CcSEcCtD
Paricalcitol—Back pain—Doxorubicin—uterine cancer	0.000305	0.000555	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—CYP11A1—uterine cancer	0.000304	0.0014	CbGpPWpGaD
Paricalcitol—Muscle spasms—Doxorubicin—uterine cancer	0.000303	0.000551	CcSEcCtD
Paricalcitol—VDR—Gene Expression—PGR—uterine cancer	0.000302	0.00139	CbGpPWpGaD
Paricalcitol—Palpitations—Epirubicin—uterine cancer	0.000301	0.000548	CcSEcCtD
Paricalcitol—Loss of consciousness—Epirubicin—uterine cancer	0.000299	0.000545	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—AKR1C1—uterine cancer	0.000298	0.00138	CbGpPWpGaD
Paricalcitol—Cough—Epirubicin—uterine cancer	0.000297	0.000541	CcSEcCtD
Paricalcitol—Nausea—Etoposide—uterine cancer	0.000294	0.000536	CcSEcCtD
Paricalcitol—Hypertension—Epirubicin—uterine cancer	0.000294	0.000535	CcSEcCtD
Paricalcitol—Ill-defined disorder—Doxorubicin—uterine cancer	0.000292	0.000532	CcSEcCtD
Paricalcitol—Anaemia—Doxorubicin—uterine cancer	0.000291	0.00053	CcSEcCtD
Paricalcitol—Myalgia—Epirubicin—uterine cancer	0.00029	0.000528	CcSEcCtD
Paricalcitol—Chest pain—Epirubicin—uterine cancer	0.00029	0.000528	CcSEcCtD
Paricalcitol—Arthralgia—Epirubicin—uterine cancer	0.00029	0.000528	CcSEcCtD
Paricalcitol—Agitation—Doxorubicin—uterine cancer	0.000289	0.000527	CcSEcCtD
Paricalcitol—Anxiety—Epirubicin—uterine cancer	0.000289	0.000526	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000288	0.000524	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—AKR1C3—uterine cancer	0.000287	0.00133	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—EZH2—uterine cancer	0.000286	0.00132	CbGpPWpGaD
Paricalcitol—Discomfort—Epirubicin—uterine cancer	0.000286	0.000521	CcSEcCtD
Paricalcitol—Malaise—Doxorubicin—uterine cancer	0.000284	0.000517	CcSEcCtD
Paricalcitol—Dry mouth—Epirubicin—uterine cancer	0.000283	0.000516	CcSEcCtD
Paricalcitol—Vertigo—Doxorubicin—uterine cancer	0.000283	0.000515	CcSEcCtD
Paricalcitol—Syncope—Doxorubicin—uterine cancer	0.000282	0.000514	CcSEcCtD
Paricalcitol—Leukopenia—Doxorubicin—uterine cancer	0.000282	0.000513	CcSEcCtD
Paricalcitol—Confusional state—Epirubicin—uterine cancer	0.00028	0.00051	CcSEcCtD
Paricalcitol—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	0.000279	0.00129	CbGpPWpGaD
Paricalcitol—Palpitations—Doxorubicin—uterine cancer	0.000278	0.000507	CcSEcCtD
Paricalcitol—Oedema—Epirubicin—uterine cancer	0.000278	0.000506	CcSEcCtD
Paricalcitol—Loss of consciousness—Doxorubicin—uterine cancer	0.000277	0.000504	CcSEcCtD
Paricalcitol—Infection—Epirubicin—uterine cancer	0.000276	0.000503	CcSEcCtD
Paricalcitol—Cough—Doxorubicin—uterine cancer	0.000275	0.0005	CcSEcCtD
Paricalcitol—Shock—Epirubicin—uterine cancer	0.000273	0.000498	CcSEcCtD
Paricalcitol—Nervous system disorder—Epirubicin—uterine cancer	0.000272	0.000496	CcSEcCtD
Paricalcitol—Hypertension—Doxorubicin—uterine cancer	0.000272	0.000495	CcSEcCtD
Paricalcitol—Skin disorder—Epirubicin—uterine cancer	0.00027	0.000491	CcSEcCtD
Paricalcitol—Hyperhidrosis—Epirubicin—uterine cancer	0.000269	0.000489	CcSEcCtD
Paricalcitol—Myalgia—Doxorubicin—uterine cancer	0.000268	0.000488	CcSEcCtD
Paricalcitol—Chest pain—Doxorubicin—uterine cancer	0.000268	0.000488	CcSEcCtD
Paricalcitol—Arthralgia—Doxorubicin—uterine cancer	0.000268	0.000488	CcSEcCtD
Paricalcitol—Anxiety—Doxorubicin—uterine cancer	0.000267	0.000487	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000266	0.000485	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—RRM2—uterine cancer	0.000266	0.00123	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—ESR2—uterine cancer	0.000265	0.00123	CbGpPWpGaD
Paricalcitol—Discomfort—Doxorubicin—uterine cancer	0.000265	0.000482	CcSEcCtD
Paricalcitol—Anorexia—Epirubicin—uterine cancer	0.000265	0.000482	CcSEcCtD
Paricalcitol—Dry mouth—Doxorubicin—uterine cancer	0.000262	0.000478	CcSEcCtD
Paricalcitol—Hypotension—Epirubicin—uterine cancer	0.00026	0.000473	CcSEcCtD
Paricalcitol—Confusional state—Doxorubicin—uterine cancer	0.000259	0.000472	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—DCN—uterine cancer	0.000258	0.00119	CbGpPWpGaD
Paricalcitol—Oedema—Doxorubicin—uterine cancer	0.000257	0.000468	CcSEcCtD
Paricalcitol—Infection—Doxorubicin—uterine cancer	0.000255	0.000465	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000253	0.000461	CcSEcCtD
Paricalcitol—Shock—Doxorubicin—uterine cancer	0.000253	0.000461	CcSEcCtD
Paricalcitol—Nervous system disorder—Doxorubicin—uterine cancer	0.000252	0.000459	CcSEcCtD
Paricalcitol—Insomnia—Epirubicin—uterine cancer	0.000251	0.000458	CcSEcCtD
Paricalcitol—Skin disorder—Doxorubicin—uterine cancer	0.00025	0.000455	CcSEcCtD
Paricalcitol—Paraesthesia—Epirubicin—uterine cancer	0.000249	0.000454	CcSEcCtD
Paricalcitol—Hyperhidrosis—Doxorubicin—uterine cancer	0.000248	0.000452	CcSEcCtD
Paricalcitol—Dyspnoea—Epirubicin—uterine cancer	0.000248	0.000451	CcSEcCtD
Paricalcitol—Somnolence—Epirubicin—uterine cancer	0.000247	0.00045	CcSEcCtD
Paricalcitol—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	0.000245	0.00113	CbGpPWpGaD
Paricalcitol—Anorexia—Doxorubicin—uterine cancer	0.000245	0.000446	CcSEcCtD
Paricalcitol—Dyspepsia—Epirubicin—uterine cancer	0.000244	0.000445	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—CYP11A1—uterine cancer	0.000243	0.00112	CbGpPWpGaD
Paricalcitol—Decreased appetite—Epirubicin—uterine cancer	0.000241	0.00044	CcSEcCtD
Paricalcitol—Hypotension—Doxorubicin—uterine cancer	0.00024	0.000437	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Epirubicin—uterine cancer	0.00024	0.000437	CcSEcCtD
Paricalcitol—Fatigue—Epirubicin—uterine cancer	0.000239	0.000436	CcSEcCtD
Paricalcitol—Constipation—Epirubicin—uterine cancer	0.000238	0.000433	CcSEcCtD
Paricalcitol—Pain—Epirubicin—uterine cancer	0.000238	0.000433	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000234	0.000426	CcSEcCtD
Paricalcitol—Insomnia—Doxorubicin—uterine cancer	0.000232	0.000423	CcSEcCtD
Paricalcitol—Paraesthesia—Doxorubicin—uterine cancer	0.000231	0.00042	CcSEcCtD
Paricalcitol—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	0.000231	0.00107	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—AKR1C3—uterine cancer	0.00023	0.00106	CbGpPWpGaD
Paricalcitol—Dyspnoea—Doxorubicin—uterine cancer	0.000229	0.000417	CcSEcCtD
Paricalcitol—Feeling abnormal—Epirubicin—uterine cancer	0.000229	0.000417	CcSEcCtD
Paricalcitol—Somnolence—Doxorubicin—uterine cancer	0.000228	0.000416	CcSEcCtD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	0.000228	0.00105	CbGpPWpGaD
Paricalcitol—Gastrointestinal pain—Epirubicin—uterine cancer	0.000227	0.000414	CcSEcCtD
Paricalcitol—Dyspepsia—Doxorubicin—uterine cancer	0.000226	0.000412	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—CYP19A1—uterine cancer	0.000224	0.00103	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—STK11—uterine cancer	0.000224	0.00103	CbGpPWpGaD
Paricalcitol—Decreased appetite—Doxorubicin—uterine cancer	0.000223	0.000407	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000222	0.000404	CcSEcCtD
Paricalcitol—Fatigue—Doxorubicin—uterine cancer	0.000222	0.000404	CcSEcCtD
Paricalcitol—Urticaria—Epirubicin—uterine cancer	0.000221	0.000402	CcSEcCtD
Paricalcitol—Constipation—Doxorubicin—uterine cancer	0.00022	0.0004	CcSEcCtD
Paricalcitol—Pain—Doxorubicin—uterine cancer	0.00022	0.0004	CcSEcCtD
Paricalcitol—Body temperature increased—Epirubicin—uterine cancer	0.00022	0.0004	CcSEcCtD
Paricalcitol—Abdominal pain—Epirubicin—uterine cancer	0.00022	0.0004	CcSEcCtD
Paricalcitol—VDR—Gene Expression—CDKN2B—uterine cancer	0.000216	0.000998	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	0.000215	0.000993	CbGpPWpGaD
Paricalcitol—Feeling abnormal—Doxorubicin—uterine cancer	0.000212	0.000386	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Doxorubicin—uterine cancer	0.00021	0.000383	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	0.00021	0.00097	CbGpPWpGaD
Paricalcitol—Hypersensitivity—Epirubicin—uterine cancer	0.000205	0.000373	CcSEcCtD
Paricalcitol—Urticaria—Doxorubicin—uterine cancer	0.000204	0.000372	CcSEcCtD
Paricalcitol—Abdominal pain—Doxorubicin—uterine cancer	0.000203	0.00037	CcSEcCtD
Paricalcitol—Body temperature increased—Doxorubicin—uterine cancer	0.000203	0.00037	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	0.0002	0.000925	CbGpPWpGaD
Paricalcitol—Asthenia—Epirubicin—uterine cancer	0.000199	0.000363	CcSEcCtD
Paricalcitol—VDR—Gene Expression—SMAD3—uterine cancer	0.000197	0.000911	CbGpPWpGaD
Paricalcitol—Pruritus—Epirubicin—uterine cancer	0.000197	0.000358	CcSEcCtD
Paricalcitol—Diarrhoea—Epirubicin—uterine cancer	0.00019	0.000346	CcSEcCtD
Paricalcitol—Hypersensitivity—Doxorubicin—uterine cancer	0.000189	0.000345	CcSEcCtD
Paricalcitol—Asthenia—Doxorubicin—uterine cancer	0.000184	0.000336	CcSEcCtD
Paricalcitol—Dizziness—Epirubicin—uterine cancer	0.000184	0.000335	CcSEcCtD
Paricalcitol—Pruritus—Doxorubicin—uterine cancer	0.000182	0.000331	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—STK11—uterine cancer	0.000179	0.000826	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CYP19A1—uterine cancer	0.000179	0.000826	CbGpPWpGaD
Paricalcitol—Vomiting—Epirubicin—uterine cancer	0.000177	0.000322	CcSEcCtD
Paricalcitol—Diarrhoea—Doxorubicin—uterine cancer	0.000176	0.00032	CcSEcCtD
Paricalcitol—Rash—Epirubicin—uterine cancer	0.000175	0.000319	CcSEcCtD
Paricalcitol—Dermatitis—Epirubicin—uterine cancer	0.000175	0.000319	CcSEcCtD
Paricalcitol—Headache—Epirubicin—uterine cancer	0.000174	0.000317	CcSEcCtD
Paricalcitol—Dizziness—Doxorubicin—uterine cancer	0.00017	0.00031	CcSEcCtD
Paricalcitol—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	0.00017	0.000784	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—MTHFR—uterine cancer	0.000168	0.000776	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	0.000167	0.000773	CbGpPWpGaD
Paricalcitol—Nausea—Epirubicin—uterine cancer	0.000165	0.0003	CcSEcCtD
Paricalcitol—Vomiting—Doxorubicin—uterine cancer	0.000163	0.000298	CcSEcCtD
Paricalcitol—Rash—Doxorubicin—uterine cancer	0.000162	0.000295	CcSEcCtD
Paricalcitol—Dermatitis—Doxorubicin—uterine cancer	0.000162	0.000295	CcSEcCtD
Paricalcitol—VDR—Gene Expression—ESR1—uterine cancer	0.000161	0.000744	CbGpPWpGaD
Paricalcitol—Headache—Doxorubicin—uterine cancer	0.000161	0.000293	CcSEcCtD
Paricalcitol—Nausea—Doxorubicin—uterine cancer	0.000153	0.000278	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	0.000148	0.000684	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—MTHFR—uterine cancer	0.000134	0.000621	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PTEN—uterine cancer	9.35e-05	0.000432	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—NDUFB11—uterine cancer	9.12e-05	0.000421	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SRD5A2—uterine cancer	9.12e-05	0.000421	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—EP300—uterine cancer	8.92e-05	0.000412	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PTEN—uterine cancer	7.48e-05	0.000345	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—EP300—uterine cancer	7.13e-05	0.000329	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PIK3CA—uterine cancer	6.6e-05	0.000305	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—AKR1B1—uterine cancer	6.59e-05	0.000305	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—STAR—uterine cancer	6.59e-05	0.000305	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—AKT1—uterine cancer	5.81e-05	0.000268	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—AKT1—uterine cancer	5.39e-05	0.000249	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PIK3CA—uterine cancer	5.27e-05	0.000244	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—POLD1—uterine cancer	5.17e-05	0.000239	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—AKR1C1—uterine cancer	4.84e-05	0.000224	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—RRM2—uterine cancer	4.31e-05	0.000199	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—AKT1—uterine cancer	4.31e-05	0.000199	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—DCN—uterine cancer	4.19e-05	0.000193	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP11A1—uterine cancer	3.95e-05	0.000182	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—AKR1C3—uterine cancer	3.73e-05	0.000172	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP19A1—uterine cancer	2.9e-05	0.000134	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—STK11—uterine cancer	2.9e-05	0.000134	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—MTHFR—uterine cancer	2.18e-05	0.000101	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PTEN—uterine cancer	1.21e-05	5.6e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—EP300—uterine cancer	1.16e-05	5.35e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PIK3CA—uterine cancer	8.56e-06	3.95e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—AKT1—uterine cancer	6.99e-06	3.23e-05	CbGpPWpGaD
